{"id":"W2034826891","doi":"10.1007/s00280-013-2078-0","title":"An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Heart, Lung, and Blood Institute; Georgia Cancer Coalition; Health Canada; National Institute on Aging; Aflac; U.S. Food and Drug Administration; National Cancer Institute; National Institutes of Health","keywords":"Bortezomib; In vivo; Protein kinase B; PI3K/AKT/mTOR pathway; Angiogenesis; Proteasome inhibitor; Phosphoinositide 3-kinase; Cancer research; Medicine; Pharmacology; Multiple myeloma; Biology; Immunology; Signal transduction; Cell biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001687905,0.0003644938,0.0003416481,0.0000817446,0.0001369453,0.00005449069,0.0002852113,0.0003594826,0.0009720444],"category_scores_gemma":[0.00001315332,0.000360552,0.00008980055,0.0001555669,0.0003618579,0.00003997918,0.00007023424,0.0003414512,0.000008828296],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001303391,"about_ca_system_score_gemma":0.0002204365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007769206,"about_ca_topic_score_gemma":0.0003555692,"domain_scores_codex":[0.9981972,0.0001333412,0.0002838572,0.0006977692,0.0001181638,0.000569652],"domain_scores_gemma":[0.9992069,0.00004168721,0.0001394133,0.0002910422,0.0001074296,0.0002135183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006039325,0.0001668877,0.01441014,0.00003973485,0.0000972749,0.000008435149,0.0002633547,0.0001085758,0.9178061,0.000002218074,0.008261505,0.05823188],"study_design_scores_gemma":[0.003318813,0.0003879503,0.006690207,0.00002481213,0.00001657819,0.0000061931,0.00005386994,0.001015517,0.9346609,0.00003647347,0.05336755,0.0004211141],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934804,0.003576613,0.0001903546,0.0009990956,0.0008766605,0.0005872037,0.0000720836,0.00004120448,0.0001763332],"genre_scores_gemma":[0.9901642,0.002754069,0.0002358959,0.00509416,0.0009838785,0.0004761365,0.00003618692,0.00006327034,0.0001922401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05781077,"threshold_uncertainty_score":0.9999412,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01321246466228843,"score_gpt":0.2847992486588463,"score_spread":0.2715867839965579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}